Zomedica Q3 net loss narrows 48% to $3.2 million as revenue rises 22% to $9.9 million
ZOM•Zomedica’s third-quarter 2026 net loss narrowed 48% year over year to $3.2 million, while revenue rose 22% to a record $9.9 million.
1. Quarterly results
Diagnostic revenue more than doubled year over year to $1.6 million, and operating expenses fell 21% to $9.5 million. Quarter-end cash, cash equivalents and available-for-sale securities totaled $40.9 million. An agreement with Veterinary Study Groups created an opportunity to bring Zomedica products to more than 2,000 independent veterinary practices.
